Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clindamycin phosphate
Drug ID BADD_D00487
Description Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris.[L11593] It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli.[A190621] Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.[A190657] Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample.[A190621]
Indications and Usage For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
Marketing Status Prescription; Discontinued
ATC Code D10AF01; G01AA10; J01FF01
DrugBank ID DB01190
KEGG ID D01073
MeSH ID C007084
PubChem ID 32603
TTD Drug ID Not Available
NDC Product Code 71872-7200; 0338-9549; 73473-302; 0404-9837; 43538-173; 17478-121; 0395-8076; 70771-1414; 17478-120; 59762-3743; 0009-5095; 71872-7189; 0009-3331; 71872-7194; 50090-0768; 63629-8634; 71872-7165; 49711-0116; 59762-5009; 0009-3448; 25021-115; 21922-036; 50090-2611; 63629-8629; 0404-9838; 0338-3612; 63629-8633; 53002-8370; 71872-7186; 51672-1400; 16714-246; 71872-7253; 0338-9553; 71872-7199; 0009-0302; 51672-4194; 71428-003; 71872-7089; 50090-1932; 45802-562; 0009-4073; 52584-870; 52584-090; 71872-7197; 63629-8628; 0009-0870; 71872-7192; 45802-900; 68981-026; 0168-0277; 63323-282; 51672-1399; 0009-3116; 46204-0120; 79572-007; 63629-8630; 69132-003; 17478-122; 72611-634; 68071-5099; 71872-7191; 72578-084; 39635-0001; 0009-0902; 0009-7667; 0009-0775; 63629-8631; 51672-4081; 51927-0184; 72611-639; 71872-7123; 58598-0003; 50090-5779; 0338-3410; 43538-171; 71872-7088; 16714-161; 68462-866; 45802-128; 67321-302; 0009-0728; 45802-660; 53002-8371; 0168-0201; 0168-0203; 0338-4114; 50090-3086; 0009-0901; 72611-645; 0009-3051; 10135-691; 51927-1683; 0338-3616; 0168-0202; 0009-3329; 73473-300; 52565-018; 71872-7284; 45802-263; 81505-100; 59762-3744; 38779-0006; 63629-8632; 0338-9545; 0009-0602; 68788-7990; 43538-172; 72611-642; 68682-462; 0378-8134; 0338-3814; 45802-042; 43538-170; 52946-0603
Synonyms clindamycin phosphate | clindamycin-2-phosphate | Clindesse | Clindets | Cleocin phosphate
Chemical Information
Molecular Formula C18H34ClN2O8PS
CAS Registry Number 24729-96-2
SMILES CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)OP(=O)(O)O)O)O)C(C)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oesophagitis07.08.05.001--
Oliguria20.01.03.004--Not Available
Pain08.01.08.004--
Polyarthritis15.01.01.005--Not Available
Proteinuria20.02.01.011--
Pruritus23.03.12.001--
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Seborrhoea23.02.07.001--Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.005--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin irritation23.03.04.009--Not Available
Stevens-Johnson syndrome11.07.01.005; 10.01.03.020; 23.03.01.007; 12.03.01.014--
Swelling face23.04.01.018; 10.01.05.018--Not Available
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tonsillitis11.01.13.006; 22.07.03.008--Not Available
Tracheitis22.07.03.009; 11.01.13.007--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal discharge21.08.02.002--
Vaginal infection21.14.02.002; 11.01.10.002--
Vaginal inflammation21.14.02.001--
Vertigo17.02.12.002; 04.04.01.003--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages